FluMist Quadrivalent

Vaccine: FluMist Quadrivalent
Company: AstraZeneca
Approval Date: Feb. 29
Protects Against: Influenza

AstraZeneca ($AZN), maker of the nasal spray vaccine FluMist, nabbed FDA approval for a quadrivalent version of the flu vaccine Feb. 29. FluMist Quadrivalent not only covers two strains of influenza A and one strain of influenza B, but it also adds protection against a second strain of influenza B. This should increase efficacy because it gives health experts and vaccine manufacturers another shot at matching a circulating strain with a strain in the vaccine. Plus, the nasal spray appeals to many who shy away from the jab of a needle.

AstraZeneca compared the quadrivalent verision with the trivalent FluMist, finding that both maintained similar safety levels. Adding the extra strain did not affect immune response.

For more:
AstraZeneca's FluMist Quadrivalent to hit U.S. market
SLU: Include both strains of influenza B in shot

FluMist Quadrivalent

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.